ECTRIMS eLearning

Upper limb function in MS: creation of a normative data set on subjective and objective measures and the construction of an MS-specific assessment tool
Author(s): ,
C. Solaro
Affiliations:
Dept. of Rehabilitation, `Mons. L. Novarese` Hospital, Moncrivello (VC)
,
G. Brichetto
Affiliations:
Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova
,
M. Mueller
Affiliations:
Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genova
,
D. Cattaneo
Affiliations:
Don Gnocchi Foundation, Milano
,
R. Bertoni
Affiliations:
Don Gnocchi Foundation, Milano
,
F. Patti
Affiliations:
MS Center Institute of Neurological Sciences, University of Catania, Catania
,
A. Pappalardo
Affiliations:
MS Center Institute of Neurological Sciences, University of Catania, Catania
,
L. Prosperini
Affiliations:
Dept. of Neurology and Psychiatry, Sapienza University, Roma
,
L. Castelli
Affiliations:
Dept. of Neurology and Psychiatry, Sapienza University, Roma
D. Marengo
Affiliations:
Department of Psychology, University of Turin, Torino, Italy
ECTRIMS Learn. Solaro C. 10/10/18; 229257; EP1418
Dr. Claudio Marcello Solaro
Dr. Claudio Marcello Solaro
Contributions
Abstract

Abstract: EP1418

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Background: There are no validated, self-administered scale that assess dimensions for upper limb functions. Proximal and distal strength may be rated using a dynamometer, although normative data are not available.
Objectives: Developing: a set of normative data for both objective and subjective measures of upper limb function and a self-administered MS-specific scale.
Methods:
Phase 1
A literature review confirmed that there is no specific measure. The panel identified 4 scales used in other neurological conditions: Manual Ability Measure (MAM-36), Disabilities of The Arm, Shoulder and Hand (DASH), Motor Activity Long (MAL)
Phase 2
Translation and adaptation of scales (MAM-36, DASH, MAL):
- the questionnaire has been fulfilled by 5 MS patients followed by second expert meeting
- the final version has been tested in the final sample
183 patients enrolled: 125 F/58 M; mean age: 47,18 years; mean EDSS: 4.05. They were evaluated using: hand-grip; 9Hole Peg Test (9HPT); Box and Block (BB); MAM-36; DASH.
Results:
Correlation between upper-extremity function tests (* p< .05 ** p< .01) BB left vs right: 0.88**; 9HPT(Right) vs BB(right): -.47**; 9HPT(Right) vs BB(left): -.38**; 9HPT(left) vs BB(right): -.35**; 9HPT(left) vs BB(left): -.41**; 9HPT(left) vs BB(right): .63**; HAND-GRIP (Right) vs BB(Right): .09; HAND-GRIP (Right) vs BB(left) -.01; HAND-GRIP (Right) vs 9 HPT(Right): -.06; HAND-GRIP (Right) vs 9 HPT(Left): 0.01; HAND-GRIP (Left) vs BB(Right): 0.01; HAND-GRIP (Left) vs BB(Left): .03; 9 HPT(Right) vs HAND-GRIP (Left): .04; HAND-GRIP (Left) vs 9 HPT(Left): -.06; HAND-GRIP (Left) vs HAND-GRIP (Right): .85**.
Discussion and conclusion: In conclusion, we found:
- A strong inter-correlation between right and left hand scores for BB, 9HPT and hand-grip
- A moderate negative correlation between BB and 9HPT (both hands), but not a correlation with hand-grip score.
- A strong negative correlation between MAM-36 and DASH and a moderate correlation of both with BB and 9HPT
Disclosure: Dr. Solaro, Dr.Patti and Dr. Prosperini served on advisory boards of the following companies: Biogen Idec, Merck Serono. He received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono, Almirall, Teva, Genzyme. He received research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla).

Abstract: EP1418

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Background: There are no validated, self-administered scale that assess dimensions for upper limb functions. Proximal and distal strength may be rated using a dynamometer, although normative data are not available.
Objectives: Developing: a set of normative data for both objective and subjective measures of upper limb function and a self-administered MS-specific scale.
Methods:
Phase 1
A literature review confirmed that there is no specific measure. The panel identified 4 scales used in other neurological conditions: Manual Ability Measure (MAM-36), Disabilities of The Arm, Shoulder and Hand (DASH), Motor Activity Long (MAL)
Phase 2
Translation and adaptation of scales (MAM-36, DASH, MAL):
- the questionnaire has been fulfilled by 5 MS patients followed by second expert meeting
- the final version has been tested in the final sample
183 patients enrolled: 125 F/58 M; mean age: 47,18 years; mean EDSS: 4.05. They were evaluated using: hand-grip; 9Hole Peg Test (9HPT); Box and Block (BB); MAM-36; DASH.
Results:
Correlation between upper-extremity function tests (* p< .05 ** p< .01) BB left vs right: 0.88**; 9HPT(Right) vs BB(right): -.47**; 9HPT(Right) vs BB(left): -.38**; 9HPT(left) vs BB(right): -.35**; 9HPT(left) vs BB(left): -.41**; 9HPT(left) vs BB(right): .63**; HAND-GRIP (Right) vs BB(Right): .09; HAND-GRIP (Right) vs BB(left) -.01; HAND-GRIP (Right) vs 9 HPT(Right): -.06; HAND-GRIP (Right) vs 9 HPT(Left): 0.01; HAND-GRIP (Left) vs BB(Right): 0.01; HAND-GRIP (Left) vs BB(Left): .03; 9 HPT(Right) vs HAND-GRIP (Left): .04; HAND-GRIP (Left) vs 9 HPT(Left): -.06; HAND-GRIP (Left) vs HAND-GRIP (Right): .85**.
Discussion and conclusion: In conclusion, we found:
- A strong inter-correlation between right and left hand scores for BB, 9HPT and hand-grip
- A moderate negative correlation between BB and 9HPT (both hands), but not a correlation with hand-grip score.
- A strong negative correlation between MAM-36 and DASH and a moderate correlation of both with BB and 9HPT
Disclosure: Dr. Solaro, Dr.Patti and Dr. Prosperini served on advisory boards of the following companies: Biogen Idec, Merck Serono. He received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono, Almirall, Teva, Genzyme. He received research grants and support from the Italian MS Society Research Foundation (Fondazione Italiana Sclerosi Multipla).

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies